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The present review focuses on the B-vitamins, i.e. folate, vitamin B12, vitamin B6 and
riboflavin, that are involved in homocysteine metabolism. Homocysteine is a S-containing
amino acid and its plasma concentrations can be raised by various constitutive, genetic and
lifestyle factors, by inadequate nutrient status and as a result of systemic disease and various
drugs. Hyperhomocysteinaemia is a modest independent predictor of CVD and stroke, but
causality and the precise pathophysiological mechanism(s) of homocysteine action remain
unproven. The predominant nutritional cause of raised plasma homocysteine in most healthy
populations is folate insufficiency. Vitamin B12 and, to a lesser extent, vitamin B6 are also
effective at lowering plasma homocysteine, especially after homocysteine lowering by folic
acid in those individuals presenting with raised plasma homocysteine. However, riboflavin
supplementation appears to be effective at lowering plasma homocysteine only in those
individuals homozygous for the T allele of the C677T polymorphism of the methylenetetra-
hydrofolate reductase (MTHFR) gene. This gene codes for the MTHFR enzyme that produces
methyltetrahydrofolate, which, in turn, is a substrate for the remethylation of homocysteine by
the vitamin B12-dependent enzyme methionine synthase. Individuals with the MTHFR 677TT
genotype are genetically predisposed to elevated plasma homocysteine, and in most populations
have a markedly higher risk of CVD.
Homocysteine: Folate: Vitamin B12: Vitamin B6: Riboflavin
Epidemiological and experimental evidence is accumulat-
ing to indicate a probable role for certain B-vitamins in the
prevention of CVD. Active forms of four B-vitamins, i.e.
folate, vitamin B12, vitamin B6 and riboflavin, are involved
in the metabolism of a S-containing amino acid, homo-
cysteine. Homocysteine metabolism links the methionine
cycle with the folate cycle (Fig. 1). In most tissues and
cells the major, or only, pathway for the conversion of
homocysteine to methionine is the transfer of a methyl
group from 5-methyltetrahydrofolate to homocysteine,
catalysed by the vitamin B12-dependent enzyme methio-
nine synthase. One product of this reaction, methionine,
can donate the methyl group via the activated form of
methionine S-adenosylmethionine to a range of substrates,
including proteins, phospholipids and DNA. The other
product of the methionine synthase reaction, tetrahydro-
folate, is reconverted to 5-methyltetrahydrofolate via
the folate cycle. The reduction of 5,10-methylenetetra-
hydrofolate to 5-methyltetrahydrofolate in the folate cycle
is catalysed by the methylenetetrahydrofolate reductase
(MTHFR) enzyme, which has a FAD (derived from
riboflavin) prosthetic group. The metabolically-active form
of vitamin B6, pyridoxal phosphate, is an enzyme cofactor
for cystathionine b-synthase, which is involved in the
catabolism of homocysteine to sulfate in the trans-
sulfuration pathway (Fig. 1).
Homocysteine and CVD
The current interest in homocysteine stems from a clinical
syndrome, homocystinuria, identified > 40 years ago
(Carson & Neill, 1962; Gerritsen et al. 1962). Homo-
cystinuria is an autosomal recessive disorder characterised
by abnormalities of the long bones, ocular lens dislocation,
mental retardation and aggressive vascular disease, in
particular venous thromoembolism (Robinson, 2000).
Classical homocystinuria is caused by a deficiency of
cystathionine b-synthase. Two other rare genetic disorders
involving deficiencies of MTHFR or methionine synthase
can also cause plasma homocysteine concentrations to rise
20-fold and homocysteine to be excreted in the urine. Each
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of these enzyme deficiencies results in similar clinical
symptoms, including aggressive vascular disease, suggest-
ing that homocysteine might be the pathogenic factor in
the vascular complications. It has been hypothesised,
therefore, that even mild elevations in plasma total
homocysteine (tHcy; hyperhomocysteinaemia) could be
causally related to CVD (McCully, 1969). Although the
inborn errors of homocysteine metabolism are very rare,
hyperhomocysteinaemia is common in many populations.
It is more common in males, rises with age and the
menopause in women, is influenced by lifestyle factors
including smoking and alcohol and can be secondary to
systemic disease (e.g. kidney dysfunction) or drug treat-
ment (de Bree et al. 2002).
Two recent meta-analyses of observational studies have
indicated that tHcy is an independent predictor of CVD
and stroke (Homocysteine Studies Collaboration, 2002;
Wald et al. 2002). The Homocysteine Studies Collabora-
tion (2002) has found stronger associations between tHcy
(measured in blood after the onset of disease) and CVD
and stroke in retrospective studies than in prospective
studies when tHcy is measured initially in blood from
individuals who at that time had no history of CVD or
stroke. A total of 5073 heart disease events and 1113
stroke events were included in the meta-analysis. After
adjustment for known cardiovascular risk factors and
regression dilution bias in the prospective studies, it was
found that a 25% lower than usual tHcy concentration
(approximately 3 mmol/l lower) is associated with an 11%
(odds ratio 0.89 (95% CI 0.83, 0.96)) lower heart disease
risk and 19% (odds ratio 0.81 (95% CI 0.69, 0.95)) lower
stroke risk. Wald et al. (2002), in a meta-analysis of
prospective studies and genetic studies that yielded similar
highly-significant results, have estimated that a 3 mmol/l
decrease in tHcy is associated with a 16 (95% CI 11, 20) %
decreased risk of heart disease and a 24 (95% CI 15, 33) %
decreased risk of stroke. In the genetic studies the
prevalence of a mutation in the MTHFR gene in disease
cases was determined and it was found that individuals
who have a cytosine to thymine substitution (correspond-
ing to an amino acid change of alanine to valine) at base
677 of the gene have decreased MTHFR enzyme activity
and higher tHcy (Frosst et al. 1995) than those with the
wild-type genotype. This mutation is a common poly-
morphism, with an average prevalence of the TT genotype
of 12% (Brattstrom et al. 1998). The genetic studies of
Wald et al. (2002) are supported by those of Klerk et al.
(2002), who in a further meta-analysis of case–control
observational studies (11 162 cases and 12 758 controls)
have found that individuals with the MTHFR 677TT
genotype have a 16% (odds ratio 1.16 (95% CI 1.05, 1.28))
higher odds of CVD compared with individuals with the
CC genotype. The genetic studies of disease risk are
susceptible to different sources of error from those
associated with the prospective studies of tHcy and disease
risk, and give evidence of associations that are neither
confounded by the usual lifestyle and socio-economic
factors nor diluted by measurement error (Wald et al.
2002). Davey-Smith & Ebrahim (2003) have concluded
that such triangulation of the associations between
genotype, tHcy and CVD risk provides robust evidence of
a general casual effect of tHcy on disease risk that would
be experienced by the whole population, independent of
genotype.
Causality of homocysteine in CVD is further supported
by studies that show that B-vitamin lowering of tHcy
decreases the rate of restenosis (Schnyder et al. 2001) and
adverse outcomes among CVD patients with successful
angioplasty (Schnyder et al. 2002), and improves vascular
endothelial function in such patients (Chambers et al.
2000).
Various pathophysiological mechanisms have been
proposed to explain the effect of tHcy on cardiovascular
risk, but there is as yet no consensus. Proposed mechan-
isms include possible effects of tHcy on endothelium
dysfunction, increased arterial intimal–medial thickness,
increased arterial stiffness, increased procoagulant activity
and age-related immune dysfunction (Mangoni & Jackson,
2002; Dawson et al. 2004). An alternative explanation is
that elevated tHcy is a reliable marker of low B-vitamin
status or decreased methylation capacity of cells; either of
these factors might be directly related to disease. Castro
et al. (2003), for example, have found that there are
increased tHcy and S-adenosylhomocysteine concentra-
tions in plasma and a lower global DNA methylation status
in leucocytes from patients with CVD compared with
matched controls. Disturbances in DNA methylation will
have effects on the control of gene expression (Frisco et al.
2002). The addition of a methyl group to cytosine in
the sequence CG is the major modification made to DNA
after new strands have been synthesised during cell
division (about 80% of the CG is methylated) and
methylation-free regions (CpG islands) tend to occur
in the promoter (control) region of genes. Methylation
of the promoter region of genes or the protein core
(chromatin) of DNA determines whether genes are active
(unmethylated) or inactive (methylated). Paradoxically,
even in the face of global DNA hypomethylation, certain
regions of the genome can be hypermethylated, and such
perturbations in DNA methylation and gene expression
could have profound effects on CVD risk (Dong et al.
2002).
The first report of a randomised controlled trial of
tHcy lowering in patients to prevent recurrent stroke (Toole
et al. 2004) does not, however, provide any evidence of
causality; albeit the authors found the expected strong
prospective association between tHcy at baseline and
vascular risk. In this trial a decrease of about 2 mmol
tHcy/l achieved by a (once daily) high-dose B-vitamin
formulation (n 1827) containing 25 mg vitamin B6, 0.4 mg
vitamin B12 and 2.5 mg folic acid v. a low-dose formula-
tion (n 1853) containing 200 mg vitamin B6, 6 mg vitamin
B12 and 200 mg folic acid after non-disabling cerebral
infarction was found to have no effect on vascular
outcomes during the 2 years of follow-up. The authors
put forward several reasons for these somewhat dis-
appointing outcomes, which include: coinciding with folic
acid fortification of the US grain supply, which profoundly
decreased the percentage of the population with folate
deficiency and thus high tHcy (from 22 before fortification
to 1.7 after fortification; Jacques et al. 1999); correction of
low serum vitamin B12 concentrations in the low-dose
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group, which may have blunted the vitamin effect; a
truncated treatment and follow-up period.
Lowering homocysteine with B-vitamins
Folate and folic acid
The folate metabolite 5-methyltetrahydrofolate is a
substrate for the enzyme methionine synthase, which
remethylates homocysteine to form methionine (Fig. 1).
Cross-sectional studies have indicated a strong inverse
association between dietary and/or blood folate concentra-
tions and tHcy concentrations (Nygard et al. 1998). The
Homocysteine Lowering Trialists Collaboration (1998)
has shown in a meta-analysis (1114 subjects in twelve
randomised trials) that supplements (0.5–5.0 mg/d) of folic
acid, the synthetic form of the B-vitamin, decrease tHcy by
about 25 (95% CI 23, 28) % (P< 0.001). In addition, there
is no difference in tHcy lowering within the range
0.5–5.0 mg folic acid/d, and folic acid is much more
effective than other B-vitamins in lowering tHcy. A more
recent study of 316 healthy older (50–75 years) Dutch
adults in a randomised double-blind placebo-controlled
trial (van Oort et al. 2003) has shown that daily
supplementation of about 400 mg folic acid/d can give
90% of the maximal decrease in tHcy. A similar adequate
dose for near-optimal lowering of tHcy by folic acid has
been reported previously by Ward et al. (1997), who found
no further decrease in tHcy with folic acid at 400 mg/d
compared with 200 mg/d in thirty healthy adults aged
34–65 years using a sequential design.
In contrast to these studies in healthy subjects, which
have indicated that doses of folic acid of <0.5 mg/d (and
largely achievable by dietary means) are adequate to effect
a maximal decrease in tHcy, Wald et al. (2001) have found
that in patients with CVD a dosage of 0.8 mg/d appears to
be necessary for maximal lowering of tHcy. However, very
recent evidence from patients with heart disease indicates
that optimal tHcy lowering may be achievable at much
lower folic acid doses (Tighe et al. 2004), similar to those
shown to be effective in healthy subjects.
Vitamin B12
In addition to 5-methyltetrahydrofolate, the remethylation
of homocysteine to methionine requires vitamin B12 as a
cofactor of the enzyme methionine synthase (Fig. 1). In the
meta-analysis of the Homocysteine Lowering Trialists’
Collaboration (1998) vitamin B12 has been found to be a
less-effective agent for lowering tHcy than folic acid, with
0.5 mg vitamin B12/d producing an additional 7 (95% CI 3,
10) % decrease in tHcy above the 25% lowering achieved
by folic acid supplements. The effect of vitamin B12 is, in
general, diminished by the larger role of folate status in
determining tHcy. Quinlivan et al. (2002) have recently
described the association between tHcy and both folate
and vitamin B12 status in two groups of healthy volunteers
pre- and post-supplementation with folic acid. They have
shown that once folate status has been optimised a clear
dependence of tHcy on vitamin B12 status emerges that
is not observed in the presupplementation period and
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Fig. 1. Pathways for the metabolism of homocysteine. 5,10-MTHFR, 5,10-methylenetetrahydrofolate reductase;
DMG, dimethylglycine. (Adapted from Robinson, 2000.)
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coincides with the loss of a correlation between tHcy and
folate status. These findings are consistent with recent
evidence from the USA that shows that in the era of folic-
acid fortification of grain foods it is vitamin B12 status (and
not folate status) that is now the major nutritional deter-
minant of tHcy in that population (Liaugaudas et al. 2001).
Although folate status is the major determinant of tHcy
in non-folic acid-supplemented populations, subgroups
within such populations may exhibit dependence of tHcy
on vitamin B12 status rather than folate. Mann et al. (1999)
have found that free-living Australian habitual meat-eaters
have lower tHcy and higher serum vitamin B12 concentra-
tions than both ovo-lacto vegetarians and vegans. Interest-
ingly, ovo-lacto vegetarians have much lower methionine
intakes than the habitual meat-eaters. Similarly, Hung et al.
(2002) have reported higher tHcy and serum folate levels
in Taiwanese vegetarians compared with omnivores, whilst
Herrmann et al. (2003) have shown that German vegans
have metabolic features that indicate vitamin B12 defi-
ciency, which lead to a substantial increase in tHcy.
Although several studies have provided dose–response
data relating to tHcy lowering by physiological doses of
folic acid, intervention studies with vitamin B12 are largely
restricted to studies undertaken >30 years ago that do not
include a measurement of tHcy (Scott, 1997), or more recent
vitamin B12 intervention studies that do include a tHcy
response but mostly focus on high (non-physiological)
doses of vitamin B12 (Ubbink, 1994; den Heijer et al.
1998).
Vitamin B6
Pyridoxal phosphate, the active form of vitamin B6, is a
cofactor for enzymes involved in amino acid metabolism.
These enzymes include cystathionine b-synthase, the first
enzyme in the trans-sulfuration pathway that breaks down
homocysteine to sulfate (Fig. 1). The meta-analysis
published by the Homocysteine Lowering Trialists’ Col-
laboration (1998) has indicated that vitamin B6 (mean
16.5 mg daily) does not have any marked tHcy-lowering
effect that is additional to that of folic acid and vitamin
B12. It is possible that an effect of vitamin B6 on tHcy
lowering has been missed in previous trials because of
the much greater effects of folic acid and/or vitamin B12.
More recently, McKinley et al. (2001) have shown in a
randomised placebo-controlled trial that a low dose of
vitamin B6 (1.6 mg/d) for 12 weeks results in a further
lowering of tHcy in healthy elderly subjects aged 63–80
years after previous repletion with folic acid (and
riboflavin). Folic acid supplementation lowers fasting tHcy
by 19.6% (P<0.001), and subsequent supplementation
with vitamin B6 (additional to folic acid) in these elderly
subjects (n 11) lowers tHcy by a further 7.5% (P=0.008),
when compared with the group (n 10) supplemented with
folic acid alone.
In the era of widespread folic acid supplementation in
the USA low vitamin B6 status, but not tHcy, has been
shown to be strongly associated with CVD in a case–
control study (Kelly et al. 2003). This finding supports
those from studies of vitamin B6-deficient monkeys and
epidemiological studies (Rimm et al. 1998) in which an
association between low vitamin B6 status and vascular
disease has been reported, which might be explained by a
relationship between inflammation and low vitamin B6
status that has been reported by Kelly et al. (2004).
Whatever the mechanism, such associations between B-
vitamin status and vascular disease suggest that tHcy might
be an indicator of low B-vitamin status rather than being
directly related to disease.
Riboflavin
The cosubstrate for methionine synthase, 5-methyltetra-
hydrofolate, is regenerated via the folate cycle and the
MTHFR enzyme, which requires FAD as a prosthetic
group (see Fig. 1). In addition, riboflavin in another active
form (FMN) is required for the generation of pyridoxal
phosphate (the active coenzyme form of vitamin B6),
which serves as a cofactor of cystathionine b-synthase and
other enzymes of the trans-sulfuration pathway.
Notwithstanding the close metabolic relationships
between riboflavin and the homocysteine and folate cycles,
a double-blind randomised placebo-controlled riboflavin-
supplementation trial in healthy elderly subjects who had a
suboptimal riboflavin status has found no effect of low-
dose riboflavin supplementation (1.6 mg/d) for 12 weeks in
lowering tHcy (McKinley et al. 2002). In this trial the
placebo group (n 22) was followed from the initial
riboflavin intervention, after which they received folic
acid (400 mg/d) for 6 weeks followed by folic acid and
riboflavin (1.6 mg/d) for a further 12 weeks and then by a
16-week wash-out period post supplementation. The
purpose of the follow-up with supplementation of the
original placebo group was to determine whether there is a
dependence of tHcy on riboflavin once folate status is
optimised and to determine whether these subjects have
tHcy that can be lowered by other B-vitamin (folic acid)
intervention. It was observed that folic acid supplementa-
tion lowers tHcy and that riboflavin supplementation
improves riboflavin status. However, it would seem that
in these volunteers, who were pre-selected for suboptimal
riboflavin status, riboflavin supplementation is not an
effective tHcy-lowering agent either before or after folate
status optimisation.
Riboflavin supplementation does not appear to lower
tHcy in the general population. However, observational
studies have shown a dependence of tHcy on riboflavin
status in those subjects homozygous (TT) for the MTHFR
C677T polymorphism (Jacques et al. 2002; McNulty et al.
2002) or for the T allele of this polymorphism (Hustad
et al. 2000). These observations are concordant with the
molecular data from in vitro studies, which indicate that
when compared with the wild-type enzyme the thermo-
labile MTHFR enzyme has an enhanced propensity to
dissociate into monomers and to lose the FAD prosthetic
group on dilution (Yamada et al. 2001).
The observational epidemiological studies, together with
data from in vitro studies, have prompted a comparison of
the effect of low-dose (1.6 mg/d) riboflavin supplementa-
tion across the three different genotypes (CC, CT and TT)
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for MTHFR. Subjects with a suboptimal riboflavin status
were randomly stratified, by screening the tHcy value
within each of the genotype groups, to receive either
treatment or a placebo for 12 weeks. Increases in riboflavin
status (approximately 10% decrease from baseline in the
erythrocyte glutathione reductase activation coefficient)
are observed for all three genotypes with riboflavin
supplementation (McNulty et al. 2003). Only in the TT
group (n 27), however, is a significant (P=0.007) decrease
( -20.8%) in tHcy observed. The percentage change in
tHcy from baseline among the CC (n 22) and CT (n 23)
groups is not significant (P=0.650 and P=0.327 respec-
tively).
These data for human subjects are, therefore, consistent
with the observational data and the current understanding
of the molecular aspects relating to the MTHFR mutant.
To this end, Stern et al. (2003) have provided data on
homocysteine methylation in cultured immortalised lym-
phocytes from individuals homozygous for the MTHFR
C677T mutation. Under adequate nutrient (i.e. folate and
riboflavin replete) conditions, the activity of the MTHFR
enzyme and the proportion of methylated folates in the
TT cells is about 50% that of CC cells, yet there is no
difference in homocysteine accumulation in the culture
medium or methionine synthetic capacity between TT and
CC cells. Only folate and riboflavin depletion together
result in marked differences between genotypes, with
decreased methionine production in TT cells compared
with CC cells. The findings, however, involve only one
immortalised cell type over a short period and the authors
acknowledge that other tissues may respond differently to
these and other nutritional perturbations.
One such nutritional perturbation may involve choline,
which through its oxidised product, betaine, can remethy-
late homocysteine via an alternative enzyme to methionine
synthase, i.e. betaine–homocysteine S-methyltransferase,
in a restricted number of tissues (Fig. 1). For example,
Schwahn et al. (2003) have found a negative correlation
between plasma betaine and tHcy in subjects with CVD.
They have also reported that hyperhomocysteinaemic
MTHFR-compromised mice appear to be much more
sensitive to changes in choline and/or betaine intake than
wild-type animals. High doses (>6 g/d) of betaine have
long been used to lower tHcy in hyperhomocystinuria,
and Olthof et al. (2003) have recently shown that
much lower doses of betaine (‡1 g/d) lead to immediate
and long-term lowering of tHcy in healthy men and
women.
Conclusions
Elevated tHcy is strongly implicated in CVD, but a cause-
and-effect relationship remains to be proven. Although
hyperhomocysteinaemia is very responsive to lowering
with folic acid in most populations, other metabolically-
related B-vitamins, particularly vitamin B12 but also
vitamin B6, have a role in preventing the elevation of
tHcy. A fourth B-vitamin, riboflavin, appears to be
important in genetic predisposition (C677T MTHFR
polymorphism) to low folate status and/or high tHcy.
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